AndhraNews.net
Home » Features » Health » Tumor

Tumor


A tumor (or tumour) is commonly used as a synonym for a neoplasm (a solid or fluid-filled cystic lesion that may or may not be formed by an abnormal growth of neoplastic cells) that appears enlarged in size. Tumor is not synonymous with cancer. While cancer is by definition malignant, a tumor can be benign, pre-malignant, or malignant, or can represent a lesion without any cancerous potential whatsoever.

The terms "mass" and "nodule" are often used synonymously with "tumor". Generally speaking, however, the term "tumor" is used generically, without reference to the physical size of the lesion. More specifically, the term "mass" is often used when the lesion has a maximal diameter of at least 20 millimeters (mm) in greatest direction, while the term "nodule" is usually used when the size of the lesion is less than 20 mm in its greatest dimension (25.4 mm = 1 inch).

Tumor in News

Basilea provides clinical program updates
Basilea Pharmaceutica AG /Basilea provides clinical program updates. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Rodney Napier -- Announces Granted Wish Surpasses 500 Wishes
CANTON, OH--(Marketwired - December 25, 2015) - Businessman and philanthropist Rodney Napier firmly believes in helping others. The charity he founded, The Granted Wish Foundation, is an extension of this philosophy

Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Novartis International AG /Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Melanoma Treatments Made Great Strides in 2015
WASHINGTON, DC--(Marketwired - December 23, 2015) - Never been has there been a more hopeful time for patients with melanoma, according to the Melanoma Research Alliance (MRA). While once almost always fatal for anyone with metastatic melanoma, recent advances in treatment, many of which came to market in 2015, have given hope of a longer life, says the MRA.

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

Market commentary: Medical technology - Gold rush times in diagnostics
Bellevue Asset Management /Market commentary: Medical technology - Gold rush times in diagnostics. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Medigene AG announces key Management Changes
Medigene AG /Medigene AG announces key Management Changes. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ImmunoCellular Therapeutics' Andrew Gengos Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - December 17, 2015) - Los Angeles-based ImmunoCellular Therapeutics Ltd.(NYSE MKT: IMUC) is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive

Four U.S. Healthcare Systems Join Guardian Research Network
SPARTANBURG, SC--(Marketwired - December 17, 2015) - The Guardian Research Network (GRN) is rapidly expanding with the addition of four partner healthcare systems including Baptist Health (Kentucky), Bon Secours Health System, Mercy and Spartanburg Regional Healthcare System, encompassing 76 hospitals in nine states.

Medigene transfers EndoTAG® to SynCore
Medigene AG /Medigene transfers EndoTAG® to SynCore. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Avant Diagnostics, Inc. Announces Launch of New Corporate Website
SCOTTSDALE, AZ--(Marketwired - December 15, 2015) - Avant Diagnostics, Inc. (OTCQB: AVDX), "Avant", unveiled its new website on December 12, 2015. The site, avantdiagnostics.com, incorporates numerous features to make browsing a more streamlined and informative experience for the Company's current and potential customers and investors

Trident Brands Appoints Dr. Julian E. Bailes Special Advisor to Brain Armor
Trident Brands, Inc. (OTCQB: TDNT), is pleased to announce the appointment of Dr. Julian E. Bailes as a Special Advisor to Brain Armor®.

Soricimed Completes Phase 1 Trial of SOR-C13 in Advanced Solid Tumour Cancers
Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, today announced that it has reached its target enrollment and treatment duration in its Phase 1 trial. The Phase 1 is designed to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other treatments

Medifocus, Inc. Announces Closing of First Tranche of Units Offering
Medifocus Inc. (TSX VENTURE: MFS) (OTCQX: MDFZF) ("Medifocus" or the "Company") announces that it has completed the first tranche of its previously announced private placement. The Company issued 78.5 Units at a price of U.S. $10,000 per Unit for gross proceeds of U.S. $785,000. Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants

Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R) (interferon gamma-1b) in Combination With Nivolumab in Patients With Advanced Solid Tumors

Prima BioMed Progresses Japanese Collaboration
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Business Wire IndiaMerck and Pfizer announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
Business Wire IndiaBoehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI), BI 1482694* (HM61713**)

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Business Wire India

Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Business Wire IndiaBoehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore, 18-21 December 2015

3-V Biosciences Announces Closing of $28.5M Financing Round
3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the closing of its Series D round of financing co-led by NEA, Kleiner Perkins and Rock Springs Capital Management and includes other new investors such as Ally Bridge Group.

Helix Announces Initiation of First Clinical Site for US Study
Helix BioPharma (TSX: HBP) (FRANKFURT: HBP) announced today that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer ("LDOS001") has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas

Medigene Receives Clinical Trial Approval for Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML)
Medigene AG /Medigene Receives Clinical Trial Approval for Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Vernalis plc: Update on AUY922 Development Programme
Vernalis plc (LSE: VER)

Medigene to participate in three international conferences in January
Medigene AG /Medigene to participate in three international conferences in January . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

The Breast Cancer Research Foundation Announces New Board Members
NEW YORK, NY--(Marketwired - December 16, 2014) - The Breast Cancer Research Foundation (BCRF) announced today the addition of three new members to its Board of Directors. William P. Lauder, Abbe Raven and Maria Baum will join the foundation's esteemed board, which is chaired by Leonard A. Lauder and Kinga Lampert.

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis International AG /Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Helix BioPharma Corp. Announces Q1 Fiscal 2015 Results
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2015, ended October 31, 2014.

Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Peregrine Pharmaceuticals, Inc

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis International AG /Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin
Novartis International AG /Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Austin Dermatologists Detail Most Effective, Least Damaging Skin Cancer Treatment
According to the Skin Cancer Foundation, every year more than two million people are diagnosed with skin cancer. Dr. Adam J. Mamelak and Dr. Miriam L. Hanson of Sanova Dermatology in Austin, TX say they routinely treat patients with a wide variety of skin cancers, including the most common form, basal cell carcinoma (BCC)

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc

Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate Cancer
KVISTGAARD, Denmark, December 10, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC®, in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

National Brain Tumor Society Announces Appointment of New Chief Executive Officer
National Brain Tumor Society, the largest nonprofit dedicated to the brain tumor community in the United States, has concluded its national search process and, today, announced the selection of Sally M. Davis as its new Chief Executive Officer.

Self Care Catalysts Partners With Carcinoid Cancer Foundation to Help Carcinoid and Neuroendocrine Tumor (NET) Patients Take Control of Their Rare Diseases
Editor's note: There is one image associated with this news release.

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that its Phase 1/2 Study of HS-410 in bladder cancer patients is open for enrollment. HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.

NuVasive(R) to Present at J.P. Morgan Healthcare Conference
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that Alex Lukianov, Chairman of the Board and Chief Executive Officer, is scheduled to present at the J.P. Morgan Healthcare Conference at the Westin St

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States

Senate Review of Innovation Act Favors Practicing Entities Like MMRGlobal
MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, "MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, applauds lawmakers of the Senate Judiciary Committee for efforts to protect the American inventor

MetaStat, Inc. Announces Issuance of U.S. Patent for Its MenaCalc(TM) Platform
MetaStat, Inc

NuVasive(R) Manufacturing, LLC., Expands U.S. Workforce to Drive Speed of Innovation(R)
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that NuVasive Manufacturing, LLC., (NML) will expand its workforce by more than 25 percent in 2014.

NuVasive(R) Further Strengthens Leadership Team in Europe
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce the continued expansion of the Company's Europe, Middle East & Africa (EMEA) leadership team, which will champion the Company's market share-taking strategy across Europe.

University of California San Diego and John Muir Medical Center Initiated Treating Patients for Colon and Lung Cancer Utilizing IsoRay's Cesium-131 Seeded Mesh
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has two new medical centers using its sutured seeds in mesh to treat colon and lung cancers.

NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium
MetaStat, Inc

Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics
Investorideas.com, an investor news and research portal issues an exclusive sector snapshot on the rapidly growing exosome market and opportunities with key insight from Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of SelectBio U.S.

Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical, Inc

Stellar Biotechnologies Announces Collaboration With Amaran Biotechnology, Inc.
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it has entered into a collaboration agreement with Amaran Biotechnology, Inc

MetaStat Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition (EMT) in Epithelial Cancers
MetaStat, Inc. (OTCQB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced that the company has entered into two separate exclusive worldwide patent and technology license agreements (the "Agreements") with The Massachusetts Institute of Technology ("MIT") and its David H

Medifocus, Inc. Announces, VM Medical Center in Montreal Has Successfully Treated Its First Patient in Its Pivotal Phase III Clinical Trial for Breast Cancer Treatment
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology
Rosetta Genomics Ltd

NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a first in human Phase 1 clinical trial of NLG919. This is NewLink's second IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor that will initially be tested in patients with recurrent advanced solid tumors

Linkage Biosciences Launches First Real-Time PCR KIR Test
Linkage Biosciences announced the launch of the first commercially available real-time PCR KIR genotyping test at the 39th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI)

Umbrella Research Initiates Coverage on TNI BioTech
TNI BioTech, Inc. (PINKSHEETS: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, is pleased to announce that Umbrella Research has initiated coverage on TNI Biotech, Inc. The full report is posted on the Company web site at http://www.tnibiotech

Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today provides commentary on a front page New York Times article published December 23, 2012 titled, "Genetic Gamble; New Approaches to Fighting Cancer."

US agency approves first obesity drug in 13 years
The US Food and Drug Administration (FDA) have approved a weight-loss pill for the first time in 13 years.

Multiple sclerosis patients at lower risk of cancer
Multiple sclerosis (MS) patients appear to have a lower cancer risk, a new research has revealed.

Spray tanning could cause cancer, docs warn
Spray tans, which are used by many as a safer alternative to sunbeds, may create serious health problems including cancer, scientists have warned.

Lazy lifestyles 'to push cancer rates up 75 pc by 2030'
Cancer rates will soar 75 percent worldwide by 2030 as developing nations adopt lazy Western lifestyles, experts have warned.

New type of prostate cancer discovered
Researchers have identified a distinct molecular subtype of prostate cancer, which appears to afflict 15 percent of patients with the disease.

Folic acid may help reduce some childhood cancers
Folic acid fortification of foods may lower the incidence of the most common type of kidney cancer and a type of brain tumours in children.

Statins could halve risk of bowel cancer
Statins, the pills taken by millions of people to combat high cholesterol, could more than halve the risk of bowel cancer, say researchers.

New jab offers cancer cure hope
A new injection, targeting the areas affected by cancer, shows promise to reduce treatment side effects and improve cure rates, researchers say.

Curry ingredient curcumin 'could be key to beating bowel cancer'
A chemical found in curry is to be tested for its ability to kill bowel cancer tumours in patients.

'Brake gene' switched off in pancreatic cancer
Researchers have explored a new class of drugs, which may bring treatment of aggressive pancreatic tumours closer to reality.

Early puberty puts girls at risk of psychological problems, early pregnancy
A new review co-authored by an Indian origin scientist has suggested that girls who start puberty very early are more likely to have psychological problems and be at risk of sexual abuse and early pregnancy.

Still no evidence that mobile phones harm human health
Scientists who looked at hundreds of studies of mobile phone exposure have found no conclusive links to cancer risk, brain function or infertility.

Family history increases liver cancer risk
Those who have a positive family history of liver cancer are more likely to develop hepatocellular carcinomas (HCC), a new study has suggested.

Smoking and not nicotine 'cuts rare tumour risk'
Researchers have confirmed a link between smoking and a reduced risk for a rare benign tumour near the brain, but the addition of smokeless tobacco to the analysis indicates that nicotine is not the protective substance.

Botanical formula shows promise to fight prostate cancer
Researchers have shed light on the effectiveness of a non-toxic, botanical formula in treating human prostate cancer in an animal model.

Soon, wonder jab that will kill 90pc of cancers
A vaccine that kills 90 per cent of cancers using the body's natural defence mechanisms could be widely available within six years, scientists say.

Caffeine plus exercise may help fight sunlight-caused skin cancer
Caffeine consumption coupled with some exercises may be able to ward off skin cancer caused by sun exposure and also prevent inflammation related to other obesity-linked cancers, suggests a new study.

Common diabetes drug 'may help prevent primary liver cancer'
Metformin, a drug that is widely used to treat Type II diabetes, may help to prevent primary liver cancer, a new study has claimed.

Avastin delays ovarian cancer progression
A targeted drug therapy called bevacizumab (Avastin), when used in combination with existing treatments like chemotherapy delays progression of advanced ovarian cancer, a new study has suggested.

Soybean compounds enhances effects of cancer radiotherapy
Compounds found in soybean compounds make radiation therapy to treat lung cancer tumours more effective, a new study has revealed.

Use of ZEN bust-enhancing supplements may increase breast cancer risk
Women who use bust-enhancing dietary supplements containing a naturally occurring toxin could be increasing their risk of breast cancer, health experts have warned.

Novel reprogramming mechanism for tumour cells discovered
Scientists have identified a protein that regulates the expression of hundreds of genes that have a crucial role in the progression of pancreatic cancer, gliomas and possibly many other kinds of tumor.

Hot chemo baths may help fight stomach and colon cancer
A handful of doctors are trying to prove that a hot chemo bath offers a fresh look at ways of fighting against even aggressive forms of stomach and colon cancer.

Why men are at higher skin cancer risk than women
Lower levels of an important skin antioxidant may be the reason behind males being more vulnerable to skin cancer than women, a new study has suggested.

Drug based on poisonous flowers could beat breast cancer
Drug extracted from one of Britain's most popular flowers 'Foxgloves' could soon be used as treatment to stop spread of breast cancer, a new study has suggested.

Soon, artificial windpipe to cut transplant rejection risk
Scientists have come up with an artificial trachea made with patient's own cells, which will help in performing successful transplant surgeries on patients suffering from tracheal tumours.

Cell phones could be 'health time bombs'
Experts have warned that mobile phones may cause serious health hazards in the near future and claimed that they could be 'health time bombs'.

Overcooked meat doubles cancer risk
Scientists have warned that overcooked meat is twice as likely to cause cancer than previously thought.

Comment on this story

Share